(Total Views: 643)
Posted On: 12/07/2022 12:54:16 PM
Post# of 154141
That was a fantastic presentation.
Drs Gluck and Sacha killed it.
Would be great if the FDA could be open to focusing on NASH just for the relevant haplotype at 700mg if nothing else, because it looks very promising and NASH will very likely need multiple drugs to treat the patient landscape anyway if and when any therapies get approved. That would be something I could see a partner getting behind.
Not sure if a long-acting NASH treatment with leronlimab is possible but with a big portion of patients being asymptomatic, stretching the injection periods out would probably make them much more amenable to receiving treatment.
I'm not planning on investing more than the small amount I currently have in the company given the market cap and financial situation but leronlimab is still as exciting as ever.
Drs Gluck and Sacha killed it.
Would be great if the FDA could be open to focusing on NASH just for the relevant haplotype at 700mg if nothing else, because it looks very promising and NASH will very likely need multiple drugs to treat the patient landscape anyway if and when any therapies get approved. That would be something I could see a partner getting behind.
Not sure if a long-acting NASH treatment with leronlimab is possible but with a big portion of patients being asymptomatic, stretching the injection periods out would probably make them much more amenable to receiving treatment.
I'm not planning on investing more than the small amount I currently have in the company given the market cap and financial situation but leronlimab is still as exciting as ever.
(8)
(0)
